Abstract: Prior phase III trials in advanced pancreatic cancer have been predominantly unsuccessful. In this review, we attempt to understand how past preclinical data were translated into phase III clinical trials in metastatic pancreatic cancer as described in the article. A systematic literature review conducted through the MEDLINE, Embase, and Cochrane Central Register of Controlled Trials databases, from January 1997 to June 2015 using key words-phase III clinical trials, metastatic/advanced pancreatic adenocarcinoma or pancreatic cancer identified 30 randomized controlled trials (RCTs) that met criteria. The trials were limited to RCTs in the firstline treatment of patients with metastatic pancreatic cancer. The success rate of first-line phase III studies in advanced pancreatic cancer was only 13%. In 60% of the RCTs, no preclinical experiments were referenced in biologically cognate pancreatic models. Nine (30%) of the RCTs were designed based on preclinical evidence from in vitro cell lines alone without additional in vivo validation in xenograft models. It remains uncertain how strongly the preclinical data influence the development of clinical regimens but so far the studies developed based on more solid preclinical evidence have been successful.
P
ancreatic cancer is the fourth leading cause of cancer related mortality in the United States and is expected to rise to the second leading within a decade. 1 The majority of the patients with pancreatic cancer have advanced disease at diagnosis with limited treatment options. Despite intensive research efforts over past several decades, the prognosis of advanced pancreatic cancer remains dismal. Even with the newest regimens, median survivals for advanced disease remain less than a year. 2, 3 Therefore, there is an urgent need for the development of new effective drugs to improve the survival of patients with metastatic pancreatic cancer.
Although we have made remarkable progress in understanding the biology of pancreatic cancer, this has not translated into new drug discovery. In fact, the only positive trials in recent years have involved traditional chemotherapy. 2, 3 Drug development in pancreatic cancer has been challenging. At least 1 issue that needs to be better understood is how preclinical data supporting the use of new agents or new combinations failed to result in clinical benefit in randomized phase III clinical trials.
The failure of clinical trials at later stages of drug development results in exposure of already symptomatic patients to unwanted toxicities causing further impairment in quality of life, waste of health care dollars, resources, and delay in development of therapies that may have a better chance of success. Preclinical data are used in the development of agents and regimens, but it remains unclear how informative these data are and how well it truly informs by the time the phase III is developed.
A diverse group of preclinical murine models have been used in cancer research. However, due to complex genetic and molecular heterogeneity in human tumors compared with mice, few, if any, of these animal models can faithfully recapitulate the in vivo pancreatic tumor microenvironment. This analysis was undertaken to better understand how past preclinical data were translated into clinical trials in pancreatic cancer. In this review, we report the preclinical rationale for all the published first-line phase III trials in metastatic pancreatic cancer as described in the article. These data may inform us in methods for improvement for future drug development in advanced pancreatic cancer.
MATERIALS AND METHODS
We conducted a systematic literature review through the MEDLINE, Embase, and Cochrane Central Register of Controlled Trials databases, from January 1997 to June 2015 using key words-phase III clinical trials, metastatic/advanced pancreatic adenocarcinoma or pancreatic cancer. The trials were limited to randomized controlled trials (RCTs) in the first-line treatment of patients with metastatic pancreatic cancer. RCTs in nonmetastatic pancreatic cancer, second-line metastatic pancreatic cancer or nonrandomized trials in metastatic pancreatic cancer were excluded. As a result, we did not include the recent successful phase III NAPOLI-1 trial in the second line setting, which has led to the US Food and Drug Administration approval of a combination liposomal irinotecan (Onivyde) regimen in pancreatic cancer patients that progressed on gemcitabine or gemcitabine-based therapies. Further, to be included, the trial had to be published. Abstract only reports were not included because background data could not be reviewed.
We identified 30 published RCTs that met inclusion criteria. Data collected from the articles included: first author, publication year, chemotherapy regimens, and information on preclinical studies. The preclinical data from published phase III trials were collected in a systematic manner. First, each published phase III study was carefully reviewed to verify that preclinical rationale was reported. If preclinical data were available, information was collected on the number and type of preclinical models tested (in vitro, cell line-derived xenograft, patient-derived xenograft [PDX] , or genetically engineered mouse model [GEMM] ) based on the reports referenced in the article. Then each study was analyzed for evidence of preclinical activity in pancreatic models and if the science for the combination drug therapy and sequencing of the drugs is proven in pancreatic cancer or not was noted. The science for the combination drug therapy was considered fully supported in pancreatic cancer only if evidence for synergy of the drug combinations was tested in pancreatic models specifically. In addition, because preclinical evidence was not always 
reported in the phase III publication, the article for the corresponding and referenced phase II study was reviewed systematically as well to note if any preclinical rationale was reported.
RESULTS
Among the 30 published randomized phase III clinical trials in the first-line in metastatic pancreatic cancer, only 3 studies had true clinical impact. The combination of gemcitabine and erlotinib had a positive trial but did not change practice in a substantive manner due to infrequent adoption by clinicians. The success rate of phase III studies in advanced pancreatic cancer was only 13% in terms of meeting primary endpoint but 10% for practice changing trials. The detailed information on preclinical evidence and models used in each RCT is listed in Tables 1 and 2 .
In the studies that reported preclinical rationale, in vitro cell lines or cell line-derived subcutaneous xenograft models were the most commonly used preclinical models (n = 27, 90%). Orthotopic xenograft models were referenced for preclinical experiments in only 5 RCTs (17%). The PDX models and GEMMs were cited in 2 RCTs (7%) and 1 RCT (3%), respectively (Fig. 1) .
In 60% of the RCT studies (n = 18), no preclinical experiments were referenced in biologically cognate pancreatic models. The sequence/schedule of the combination therapy was not tested in 22 (73%) studies. Synergy for the combination was reported for 18 (60%) of the phase III studies. Overall, references for the science for the combination drug regimen was referenced in pancreatic cancer models in only 6 (20%) of the studies.
Nine (30%) of the RCTs were designed based on preclinical evidence from in vitro cell lines alone without additional in vivo validation in xenograft models. Common examples of drugs tested in vitro alone were the combination of gemcitabine with 5-flourouracil, irinotecan, oxaliplatin, S-1, exatecan, and pemetrexed. The cell line-derived subcutaneous xenograft models were reportedly used in 15 (50%) of the 30 phase III studies.
When compared with the negative RCTs, we noted the recent positive RCTs, such as gemcitabine and nab-paclitaxel had extensive preclinical testing done in multiple preclinical models including PDX and GEMMs.
DISCUSSION
The failure rate of phase III clinical trials in advanced pancreatic cancer is high (87%). This analysis was undertaken to see if there might be information gleaned from the use of preclinical models in developing regimens that make it to phase III. There are several difficulties inherent in evaluating the impact of preclinical study on subsequent phase III success rate. First, there are only 4 positive phase III trials in first-line metastatic pancreatic cancer during the 18 years covered in this analysis, of which only 3 (10%) could be considered practice changing.
Second, preclinical data that set the rationale for the drug used or drug combinations may not all be referenced in the articles for many reasons. Article page limit may reduce the amount of introduction in the article where most of the rationale is outlined; for example, the steps between preclinical data and phase III analysis can be myriad and often include phase I and II trials. Therefore, some of the preclinical data may simply not have been included in the articles for sake of brevity. Many of the regimens come from work done within the pharmaceutical industry, and some of the data may be unpublished, limiting the ability to reference the data. Other preclinical data may have only been in abstract form at national or international meetings, limiting the likelihood it will be used as a reference. Nonetheless, the reality exists that many of the publications relevant to pancreatic cancer RCTs did not reference preclinical data in pancreatic models. We did not do an analysis of the novel agents to see where in the "life cycle" the pancreatic cancer trial occurred. In other words, when a company decides to bring an agent out of the preclinical realm into clinical development, there are primary targets that "lead off " the pipeline, and thereafter, secondary targets that are either planned later or come from outside leads. The vast majority of preclinical data are developed to establish or refute the rationale in the primary target diseases. The phase III trial may be then undertaken based on early phase clinical evidence, which would logically trump the need for preclinical evidence. In fact, in this analysis, very few, if any of the agents studied were primarily purposed for pancreatic cancer, including gemcitabine that was initially developed in lung cancer primarily, with hopes for effect in colorectal cancer as well.
The authors of this article are unaware of a systematic analysis of how much preclinical evidence is needed to bring an agent into a clinical trial. However, in pancreatic cancer, a State of the Science meeting attempted to define loose guidelines for preclinical evidence. Several conclusions about preclinical models were reached including: older models are flawed; newer models need to be interrogated and to fully test a hypothesis, more than 1 model should be used. 110 It is noted that all of the trials that were positive had agents or combinations that were tested in multiple cell lines and/or models. Of the 3 combination trials, 2 of 3 were tested in pancreatic models and all 3 had synergy data presented in the references. This suggests at least that trials with more solid preclinical evidence have been successful even if some of the data are derived in models of other cancers.
The data presented here do show that there is no uniformity in developing the rationale for use of drugs or drug combinations in phase III trials. The clear, but broad recommendations from the 2007 State of the Science meeting were made with regard to developing clinical regimens in pancreatic cancer. 110 Those guidelines are as yet untested, but these data suggest they may indicate a better way to move forward. An analysis of published phase II reports may be conducted to analyze if more robust preclinical data before phase II leads to greater likelihood of moving to phase III, but this would be flawed as an accompanying article demonstrates that robust phase II data has not been required to go to phase III trials in the past and, in fact, many studies went to phase III despite negative phase II data.
Finally, it remains uncertain how strongly the preclinical data influences the development of clinical regimens. Is compelling science the rationale used to justify conducting a pivotal trial, or are many of these studies "trials of convenience"? Irrespective, with the exceptionally low success rate for clinical trials in pancreatic cancer (and, in fact, in most cancers), it is clear that we need to reevaluate how we have been developing our trials and designing our regimens. This article is not meant as any indictment of the past, but instead, it is meant to start that discussion. 
